modelReserpineAndDiureticsCom

Diagram of ReserpineAndDiureticsCom

Extends from Pharmacolibrary.Drugs.ATC.C.C02LA51.

Information

name:ReserpineAndDiureticsCombinationsWithOtherDrugs
ATC code:C02LA51
route:oral
compartments:1
dosage:0.25mg
volume of distribution:250L
clearance:14L/h
other parameters in model implementation

This drug consists of reserpine, a rauwolfia alkaloid that acts as an antihypertensive by interfering with the storage of neurotransmitters in adrenergic neurons, combined with diuretics to enhance blood pressure-lowering effects. Such combinations have historically been used in the treatment of hypertension, but the use of reserpine has declined with the advent of more modern antihypertensive therapies. Currently, resperine combination products are rarely used and not considered first-line therapy in most international guidelines.

Pharmacokinetics

Pharmacokinetic parameters are estimated for the combination of reserpine and diuretics (representing typical adult population, oral administration), as no published studies specifically address PK of this fixed-dose combination. Parameters are based on typical single-agent PK for reserpine and known properties of oral diuretics in fixed combinations.

References

    Parameters

    TypeNameDefaultDescription
    Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
    Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
    Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
    Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
    Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
    Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
    Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
    Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
    IntegeradminCount (from PK_1C)8number of dose administered (1)
    Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
    Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
    Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
    Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
    Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

    Connectors

    TypeNameDefaultDescription
    Types.ConcentrationOutputC_central (from PK_1C)
    Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

    Components

    TypeNameDefaultDescription
    Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
    Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
    Sources.PeriodicDoseperiodicDose (from PK_1C)
    Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

    Revisions

    • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)